Respiratory syncytial virus is associated with a higher disease burden than influenza and SARS-CoV-2 in adults with chronic lung disease: a multi-center cohort study

呼吸道合胞病毒在患有慢性肺病的成年人中造成的疾病负担高于流感和SARS-CoV-2:一项多中心队列研究

阅读:2

Abstract

BACKGROUND: Comparative data on the disease burden of respiratory syncytial virus (RSV) versus other respiratory viruses in adults with chronic lung disease (CLD; asthma, COPD, or bronchiectasis) remain limited. This study aimed to compare clinical outcomes associated with RSV, influenza, and SARS-CoV-2 in this population during a period that largely preceded widespread adult RSV vaccine uptake. METHODS: Adult patients diagnosed with CLD and confirmed to have RSV, influenza, or Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection through combo tests including polymerase chain reaction or rapid antigen testing from June 2022 to April 2024 were included. A total of 82,871 participants diagnosed with CLD who tested positive for RSV, influenza, or SARS-CoV-2 using combo tests were included in the analysis. Patients with co-existing viral infections were excluded. Short-term adverse outcomes were defined as events occurring within 28 days after the index date, while long-term adverse outcomes were defined as events that occurred between 12 to 52 weeks. RESULTS: After propensity score matching, RSV-infected patients had higher rates of exacerbations compared to those with influenza (HR:1.37, 95% CI:1.28–1.47) and those with SARS-CoV-2 (HR:2.98, 95% CI:2.73–3.26). These patients also showed an increased requirement for mechanical ventilation compared to those with influenza (HR:1.50, 95% CI:1.29–1.75) and those with SARS-CoV-2 (HR:1.97, 95% CI:1.67–2.33). Additionally, RSV-infected individuals experienced higher incidences of acute decompensated heart failure compared to influenza (HR:1.32, 95% CI:1.20–1.46), and (HR:1.46, 95% CI:1.32–1.61) relative to SARS-CoV-2, respectively. CONCLUSIONS: RSV infection in patients with CLD revealed higher disease severity compared to influenza and SARS-CoV-2, warranting increased clinical attention for this population. SUMMARY: In this national cohort spanning June 2022 to March 2024, adults with chronic lung disease contracting RSV, influenza or SARS-CoV-2 were analyzed. Relative to the other viruses, RSV infection led to higher emergency visits, hospitalizations and mechanical ventilation, highlighting an urgent prevention gap. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-026-03526-4.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。